Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
-
Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected...
-
SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
-
SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
-
SAN FRANCISCO and WALTHAM, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
-
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead...
-
SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
-
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two- or three-month dosing Initial subcutaneous...
-
SAN FRANCISCO and WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic...
-
SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic...